Skip to content
NeuroTechGuide

NeuroXess raises RMB 700 million to take its wireless brain implant through registration trials

The Shanghai company's Series B will fund a multicenter registration trial, a mass-production plant and speech and vision BCIs.

2 min readFundingImplantsClinical trials

Shanghai-based NeuroXess (脑虎科技) has closed a Series B round of RMB 700 million (nearly $100 million), according to Chinese business outlet PEdaily, reported on October 28. SDIC Juli, Shenzhen Capital Group and Qinzhi Capital co-led the round. About a dozen other investors joined, including IDG Capital and SMIC Capital, along with returning backers Shanda and Zhongping Capital.

What the company is building

NeuroXess was founded in 2021 by Tao Hu, who serves as CEO and chief scientist. It develops flexible electrodes that sit on the surface of the brain beneath the dura, a semi-invasive approach similar to ECoG. The battery and processor are implanted under the skin of the chest, and power and data travel wirelessly. The company calls this a fully implanted, fully wireless system. It says the system can decode attempted movement and speech and control external devices.

The company reports 65 clinical cases completed so far. On July 7, 2026, it began a registration trial led by Prof. Mao Ying at Fudan University’s Huashan Hospital, with nearly 20 major hospitals taking part. NeuroXess says it is the first subdural semi-invasive BCI in China to enter a Class III registration trial with the National Medical Products Administration (NMPA).

The money will go to the multicenter trial and regulatory filings, and to a planned 14,300-square-meter production plant. It will also fund next-generation products, including speech and vision BCIs, and work on combining BCIs with AI.

Why it matters

  • The round adds to a run of large investments in Chinese implanted BCIs, following StairMed’s Alibaba-led raise and approval of Neuracle’s NEO system.
  • A registration trial is the last step before NMPA can approve a device for sale, so NeuroXess could be among the next Chinese BCIs to reach the market.
  • Caveats: the case count and production plans come from the company and have not been independently verified. The round also lands days after the US Treasury proposed barring most new US investment in Chinese BCI companies.

Learn more: Brain-computer interface · NeuroXess in the Directory

Share:XLinkedInBlueskyEmail

More news